glp-1 diarrhea lawyer in louisiana gastric intestinal obstruction attorney GLP-1 Medication in Georgia-mvanhaasteren.nl glp-1 law firm in – glp-1 gi obstruction attorney in

The parenteral segment held the highest market share in 2023 and is anticipated to retain this trend through 2032

Soliqua 100/33 (active ingredients: insulin glargine and lixisenatide) subcutaneous injection Initial FDA Approval: 2016 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting

Maria J

These patients should be followed more closely ( Table 1 )